Effects of the sodium–glucose co-transporter 2 inhibitor dapagliflozin in patients with type 2 diabetes and Stages 3b–4 chronic kidney disease

Mostrar otras versiones (1)

BACKGROUND: The sodium–glucose co-transporter 2 inhibitor dapagliflozin decreases haemoglobin A1c (HbA1c), body weight, blood pressure (BP) and urinary albumin:creatinine ratio (UACR) in patients with type 2 diabetes. The efficacy and safety of this drug have not been properly defined in patients wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Dekkers, Claire C J, Wheeler, David C, Sjöström, C David, Stefansson, Bergur V, Cain, Valerie, Heerspink, Hiddo J L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
ORIGINAL ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6212718/
https://www.ncbi.nlm.nih.gov/pubmed/29370424
http://dx.doi.org/10.1093/ndt/gfx350

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6212718/
https://www.ncbi.nlm.nih.gov/pubmed/29370424
http://dx.doi.org/10.1093/ndt/gfx350

Ejemplares similares